Verbesserung der Technologien zur Herstellung hochaffiner natürlicher TCRs mit erhöhter Empfindlichkeit und Sicherheit. Die Allo-Priming-Technologie liefert stärkere und nachhaltigere Immunantworten von TCRs, ohne dass eine Affinitätsreifung erforderlich ist. Standardisierungswerkzeuge wie JOVI Tag ermöglichen die Anreicherung von rekombinanten TCR (rTCR) -exprimierenden T-Zellen, um die Auswahl sicherer TCRs zu erleichtern.
TCR Generierung & Optimierung Publikationen
TCR Generierung Abstracts
ICGT
MDG1015: a 3rd Generation TCR-T Therapy Incorporating the PD1-41BB Costimulatory Switch Protein,
Advancing to the Clinic
Kirsty Crame
Präsentation
CIMT
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Julia Bittmann, Melanie Salvermoser, Dominik Alterauge, Anne-Wiebe Mohr, Doris Brechtefeld, Mario Catarinella, Petra U Prinz, Maja
Buerdek, Kathrin Davari, Dolores J Schendel and Giulia Longinotti
Poster
7th International Neoantigen Summit
KRAS Mutation-Specific TCR-T Cells are Empowered for Improved Multi-Functionality & Durability by Inclusion of a Costimulatory Switch Protein
Giulia Longinotti
Präsentation
AACR
TCR-gated control of costimulatory switch protein (CSP) activation in rTCR-T cells expressing PD1-41BB
Maja Buerdek, Petra U. Prinz, Kathrin Mutze, Andrea Coluccio Stefanie Tippmer, Miriam Bosch, Giulia Longinotti, Mario Catarinella, Kathrin Davari, Christiane Geiger, Barbara Loesch, Kirsty Crame, Dolores J. Schendel
ELRIG-Forum
Evolution by Innovation: Connecting the Dots for TCR-T Therapies
Barbara Lösch
Präsentation
CAR-TCR Summit Europe
Developing Effective Methods to Monitor, Track & Assess T-Cell Efficacy In Vivo & In Vitro
Dolores J Schendel
Präsentation
SITC
A novel library of optimal affinity KRAS mutation-specific T cell receptors associated with multiple HLAs, in combination with a PD1-41BB armoring and enhancement costimulatory switch receptor
Dolores J Schendel, Giulia Longinotti, Mario Catarinella, Melanie Salvermoser, Julia Bittmann, Kirsty Crame, Kathrin Davari and Selwyn Ho
Poster
ESMO
Mitigation of Tumor Microenvironment-Mediated Immunosuppression Using a PD1-41BB Switch Protein with Optimal Affinity TCRs for First-In-Class, 3rd Generation TCR-T Therapies
Kirsty Crame, Giulia Longinotti, Mario Catarinella, Petra U Prinz, Stefanie Tippmer, Kathrin Mutze, Andrea Coluccio, Melanie Salvermoser, Julia Bittmann, Maja Buerdek, Barbara Loesch, Christiane Geiger, Kathrin Davari, and Dolores J Schendel
CAR-TCR Summit Boston
Improving TCR-T Therapeutic Persistence and Efficacy with Switch Receptors; Dolores Schendel
Immuno-Oncology Summit Europe
PD1-41BB Switch Receptor Technology Added to TCR-Ts Further Enhances Antitumor Activity in vitro and in vivo compared to TCR alone Barbara Lösch
AACR
T cells co-expressing a highly potent NY-ESO-1-specific TCR and a chimeric PD1-41BB co-stimulatory switch receptor show a favorable polyfunctional profile for the treatment of solid tumors Andrea Coluccio, Stefanie Tippmer, Kathrin Mutze, Petra U Prinz, Maja Buerdek, Barbara Loesch, Kathrin Davari, Giulia Longinotti, Dolores J Schendel
CAR-TCR Summit
Combined Molecular & Cellular Tools are Required to Assess Safety of TCR-T Immunotherapies; Tristan Holland
SITC Annual Meeting 2020
Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy; Davari K, Holland T, Prassmayer L, Longinotti G, Ganley K, Pechilis LJ, Diaconu I, Nambiar PR, Magee MS, Schendel DJ, Sommermeyer D and Ellinger C
CIMT – Annual Meeting of the Association for Cancer Immunotherapy 2019, Mainz, Germany
A safe and highly active NY-ESO-1/LAGE-1-specific TCR for adoptive T cell therapy of cancer; Longinotti G, Bürdek M, Weis M, Raffegerst S, Mösch A, Schendel DJ, Wehner C
AACR – American Association for Cancer Research Annual Meeting 2017, Washington, D.C., USA
WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival; Iris Bigalke, Guri Solum, Dag Josefsen, Yngvar Fløisand, Kirsti Hønnåshagen, Lisbeth Skoge, Signe Spetalen, Stein Sæbøe-Larssen, Dolores J. Schendel, Gunnar Kvalheim.
Isolation and characterization of a PRAME-specific TCR with high avidity, potent antitumor efficacy and a favorable preclinical safety profile; Manon Weis, Carina Wehner, Christian Ellinger, Susanne Wilde, Dolores J. Schendel. Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany
SITC – Society for Immunotherapy of Cancer Annual Meeting 2014, National Harbor MD, USA
Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Weis M., Longinotti G., Sailer N., Schendel D.J., Milošević S. 2014. Generation of tumor antigen specific CD4+ and CD8+ T cells by simultaneous MHC-I and –II epitope presentation in vitro and in vivo. SITC National Harbor, USA.
CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz
Ellinger C., Wehner C., Wilde S., Schendel D.J., Milošević S. Mai 2013. MHC Class-II Expression Targeting (CrossTAg) for the Generation of Tumor-Antigen-Specific CD4+ T Lymphocytes. CIMT Mainz, Germany.
CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz
Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Schendel D.J., Milošević S., 2013. Isolation of antigen-specific CD8+ T lymphocytes and molecular characterization of antigenic epitopes. CIMT Mainz, Germany.
Cellular Therapie International Symposium 2013, Erlangen
Wilde S., Mosetter B., Wehner C., Ellinger C., Milosevic S., Frankenberger B., Schendel D. 2013. Isolation of NY-ESO-1-specific T cell receptors restricted by non-HLA-A*02:01 allotypes for TCR gene therapy. Cellular Therapie International Symposium Erlangen, Germany.